BioVenture

Shanhai Innovation is a biological development company focused on supramolecular science and technology research and development. It provides supramolecular material, organic liquid, ionic salt, and biocatalysis. It serves biomedicine, daily cosmetics, health food, medical equipment, and food additives.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.

Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Secretech is a research and development-driven biotechnology company focused on creating biomarkers and cellular exosomes. It specializes in developing a molecular detection technology platform designed to offer innovative solutions across scientific, clinical, and drug discovery sectors. The company is dedicated to advancing a new generation of molecular detection methods, integrated with advanced computational biology algorithms. This approach enables Secretech to deliver robust proteomics analysis tools that facilitate the rapid discovery of new molecular markers.

Chuanxin Biotech is an RNA drug research and development service provider.

Changsha Morning Shine is an innovative pharmaceutical company that specializes in R&D outsourcing, biomedicine, chemical drugs, and biotechnology services.

Shanghai Kechow Pharma is a biopharmaceutical company based in Shanghai that pursues novel drug discovery with a focus on oncology. It develops targeted small molecule therapies and participates in co-development with partners, covering research, clinical development, and regulatory registration. Founded in 2014, the company emphasizes creating new anti-cancer drugs to address clinical needs and strives to bring high-quality oncology treatments to patients.

Gachun Biotech is a pharmaceutical intermediates industrialization platform that focuses on APIs, or pharmaceutical intermediates.

Huili Pharmaceutical is a drug delivery platform that specializes in the development of nanoparticles and microsphere preparation equipment.

Essentia Biosciences is a biotechnology company that specializes in the development of cells, gene technology drugs, and medical devices.

Gene Cradle is a genetic company that develops gene therapy drugs to treat rare genetic diseases as well as chronic diseases.

Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs.

Ruoyi Biotech is a developer of macromolecular drug delivery technology.

Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, specializing in biopharmaceutical development and manufacturing services. Established in 2013, the company offers a wide range of services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. It also supports clients with technical transfer, regulatory guidance, and project management to ensure a comprehensive solution throughout the biopharmaceutical development lifecycle. Chime Biologics focuses on delivering customer-centric, cost-effective, high-quality services that cater to the evolving needs of the biopharmaceutical industry, facilitating early-stage development through late-stage clinical research and commercial production.

Hanchao Pharmaceutical is a biopharmaceutical company that specializes in the development and production of medical equipment and solutions for the biomedical industry. The company's core focus is on providing single-use bioprocessing solutions, with a particular emphasis on biomedical production technology. Hanchao independently designs, manufactures, and sells a range of equipment and consumables, catering to the industrialization stage of various biomedical fields, including antibodies, vaccines, antibody-drug conjugates (ADCs), and cell and gene therapies (CGTs).

Lealing Biotech developes anti-body based drugs and pharmaceutical products.

ProxyBio develops treatment and pharmaceutical products for mRNA development.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Resproly specializes in the research, development, production, and sales of respiratory inhalation formulas and equipment. The company focuses on clinically demanding treatment areas such as asthma, COPD (Chronic Obstructive Pulmonary Disease), diabetes, and Parkinson's disease.

Biocreatech is a biotechnology firm that uses protein design and synthetic biology to create cell factories capable of producing a range of products such as drug intermediates, fine chemicals, functional peptides, and therapeutic proteins. They involve in integrating multiple proteins into molecular machines in order to transform cells into factories.

Enzymaster (Ningbo) Bio-Engineering Co., Ltd. is a biotechnology company focused on the development and commercialization of innovative enzyme catalysis technologies. Founded in 2013 and based in Ningbo, China, the company specializes in the production of custom enzymes and biocatalytic synthesis for various applications, including active pharmaceutical ingredient intermediates, fine chemicals, and consumer goods. Enzymaster's product portfolio features compounds such as L-tert-leucine, Methyl (R)-3-Hydroxybutyrate, and D-Calcium Pantothenate. The company employs advanced techniques in enzyme-directed evolution, strain engineering, and fermentation process development to promote environmentally friendly and safe manufacturing practices across industries such as pharmaceuticals, food, and environmental conservation. Enzymaster is committed to sustainable practices and aims to contribute positively to society and the environment through its carbon-neutral intelligent manufacturing processes.

Farber Xintian CRO company engaged in clinical services of radionuclide drugs. The company focuses on the field of nuclide drugs. Through cooperation with domestic experts in the field of nuclide drugs, the company introduces IP and relies on its own resource advantages to create a VIC model for domestic nuclide drugs.

Juncell Therapeutics is a biopharmaceutical company focused on developing innovative therapies for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are then cultivated outside the human body before being reintroduced to patients, aiming to enhance the body's ability to combat tumors while minimizing side effects. Through its research and development efforts, Juncell Therapeutics seeks to advance treatment options in the medical industry, ultimately improving patient outcomes in cancer therapy.

InnoBM Pharmaceuticals is a company specializing in the development of biomaterials and pharmaceutical products. It focuses on creating novel therapeutics aimed at enhancing the efficacy of tumor immunotherapy, thereby addressing critical needs in cancer treatment. By committing to innovation, InnoBM Pharmaceuticals strives to improve outcomes for cancer patients through advanced therapeutic solutions.

Guangwei Pharmaceuticals is a pharmaceutical manufacturer in China that produce medical theater products.

Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs.

Tripod Preclinical Research is a Contract Research Organization that specializes in preclinical research services tailored for the biopharmaceutical industry. The company offers a comprehensive range of services, including nonhuman primate disease models, pharmacological efficacy assessments, early drug evaluations, and GLP toxicology. Tripod is committed to supporting global pharmaceutical companies, research and development enterprises, and medical device manufacturers in the evaluation of new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Additionally, the organization provides technology support in areas such as translational medicine, clinical trials, biological analysis, and the management of biological sample banks, ensuring that its clients have the necessary resources to advance their research and development efforts effectively.

Boan Biotech is a biopharmaceutical company focused on developing therapeutic antibodies for oncology, metabolism, autoimmunity, and ophthalmology. It conducts development, manufacturing, and commercialization of biologics and serves customers in China and international markets, with operations based in Shandong, China.

Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic illnesses, and cancer. Utilizing advanced gene editing and genomic technologies, the company creates programmable medicine that offers targeted treatments for patients. By harnessing the potential of genome editing, Reforgene Medicine seeks to improve patient outcomes and contribute to the advancement of personalized healthcare solutions.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Tavotek Biotherapeutics is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with significant unmet medical needs in cancers, autoimmune conditions, and infectious diseases. The company utilizes three platform technologies—TavoSelect, a phage display library; TavoPrecise, an engineering platform for tissue-specific biologics; and TavoMIP, a multicyclic peptide platform—to advance a diverse pipeline across multiple development stages. Its leadership includes veteran pharmaceutical executives and advisors with experience in bringing biologics to market.

Pro-Heal Pharmaceuticals is a biotechnology company that specializes in the development and manufacturing of pharmaceutical products. It focuses on creating drugs for ophthalmic and autoimmune diseases, addressing critical needs in the pharmaceutical field. By concentrating on biological macromolecule therapies and ophthalmology medicines, Pro-Heal aims to provide effective treatments that are currently lacking in clinical settings, thereby improving patient outcomes. The company's commitment to innovation and development positions it as a valuable player in the healthcare industry, dedicated to meeting urgent medical needs.

Kyinno is a biopharmaceutical company specializing in the development of oncology drugs. Its focus lies in immune treatments against cancer and next-generation kinase inhibitor design.

VesiCURE Therapeutics is a biotechnology company based in Suzhou, Jiangsu, China, founded in 2021. It specializes in the research and development of innovative drugs utilizing exosomes, also known as extracellular vesicles. The company is dedicated to advancing the understanding and application of exosomal drugs, contributing to the growth and enhancement of the exosomal pharmaceutical industry. Through its research initiatives, VesiCURE aims to promote the development of effective therapies that harness the unique properties of exosomes for medical applications.

PegBio is a biopharmaceutical company based in Suzhou, focused on polyethylene glycol (PEG) chemistry and PEGylation technology to develop and manufacture PEGylated drugs as potential new molecule entities. The company offers PEG synthesis and PEGylation services, including N-terminal specific, thiol-selective, and enzymatic PEGylation, along with pharmaceutical-grade PEGs and activated PEGs for research and pharmaceutical applications. It provides PEGylation services to universities, research institutes, and pharmaceutical companies and develops PEGylated peptides and antibody fragments for therapeutic areas such as type II diabetes and rheumatoid arthritis. PegBio also develops PB-119, a glucagon-like peptide-1 (GLP-1) receptor agonist designed for less frequent dosing, and engages in collaborations with strategic partners to modify macromolecules and advance PEGylated biopharmaceuticals.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

EOC Pharma Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. It specializes in the development, manufacturing, and commercialization of innovative oncology products. EOC employs a licensing model to enhance its product pipeline by incorporating molecules from global biopharmaceutical partners into its robust local infrastructure, which includes manufacturing, clinical development, regulatory filing, and commercialization. The company has a diverse pipeline featuring seven novel products, several of which are positioned as potentially first- and best-in-class. EOC has achieved regulatory milestones with four Class I innovative drug approvals and has initiated clinical studies for its leading products. The company operates an 8,000 square meter cGMP manufacturing facility in Taizhou and maintains offices in key locations, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team of experienced professionals, EOC aims to establish itself as a leader in oncology innovation in China through strategic partnerships and a comprehensive integrated platform.

Allist Pharmaceuticals is a pharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative medicines, particularly in the field of cancer treatment. The company is driven by the unmet clinical needs within the global pharmaceutical market and is committed to advancing long life through scientific and technological innovation. Allist Pharmaceuticals aims to create safe, effective, and inclusive drugs, holding independent intellectual property rights for its products.

Shanton Pharma Co., Ltd. is a biotechnology research organization founded in 2016 and based in Shanghai, China. The company specializes in the research and development of innovative therapies aimed at addressing significant unmet medical needs, with a particular focus on uric acid metabolism, inflammatory pain, and gout metabolic syndrome diseases. Shanton Pharma has dedicated substantial efforts to the field of gout diseases, where it has developed a promising product, SAP-001, which has demonstrated safety and efficacy. The company aims to commercialize its core products and deliver innovative new medicines to patients and the medical community.

Innovita Biological Technology Co., Ltd., established in 2006 in Beijing, is a Chinese biotechnology company specializing in the research, development, manufacturing, marketing, and after-sales service of in-vitro diagnostic tests. In 2011, the company expanded by opening a new facility in Tangshan, Hebei province, which includes five production lines for colloidal gold, real-time PCR, chemiluminescence, ELISA, and biochips. This facility spans 250 acres and features a 4,000-square-meter purification plant, with a designed annual output of up to 20 million tests. Innovita holds ten invention patents and has received certifications such as CE, ISO 13485, and GMP. Its extensive product line includes tests for fertility, infectious diseases, sexually transmitted diseases, respiratory diseases, drug abuse, tumor markers, and cardiac markers.

Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies, specifically targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in the biotechnology sector. By providing antibody-based drugs that enhance immune system functionality, along with technical consultation and drug quality inspection services, Kanova enables its clients to improve drug quality and efficiently advance the field of biomedicine.

YXgene is a Pharmaceutical company for development of virus vectors, preclinical studies and investigational new drug application

Founded in 2013, LAM Therapeutics develops precision therapeutics and companion diagnostics for cancer and rare diseases. Its pipeline includes LAM-001 for lymphangioleiomyomatosis, LAM-002 for B-cell non-Hodgkin lymphoma, and other clinical stage drugs.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

Genowise is a company specializing in advanced genetic testing and medical diagnostic services. It offers a range of services, including pharmacogenomics, auxiliary diagnosis, and tumor genome diagnosis. Genowise has developed next-generation gene sequencing reagents and a clinical data analysis system to enhance the effectiveness of genetic testing. The company provides over 15 different genetic testing kits that cover more than 170 diseases and assess over 810 known gene loci, facilitating better health management for patients. Through its innovative approach, Genowise aims to improve diagnostic accuracy and support personalized medicine initiatives.

Shanghai Kechow Pharma is a biopharmaceutical company based in Shanghai that pursues novel drug discovery with a focus on oncology. It develops targeted small molecule therapies and participates in co-development with partners, covering research, clinical development, and regulatory registration. Founded in 2014, the company emphasizes creating new anti-cancer drugs to address clinical needs and strives to bring high-quality oncology treatments to patients.

Aixing Biotechnology manufacture biopharmaceutical and IVD equipment for healthcare services.

Ascentage Pharma is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancers, hepatitis B virus (HBV), and age-related diseases. Its pipeline comprises seven drug candidates targeting protein-protein interactions and tyrosine kinases.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Eddingpharm, established in 2001, is a pharmaceutical company focused on supplying high-quality patented and branded drugs to the Chinese healthcare market. The company aims to bridge the gap between Chinese patients and global medicines by acquiring classic branded medications from multinational corporations and introducing innovative patented drugs. Eddingpharm has rapidly expanded its operations across China, deploying nearly 1,000 professional representatives in 30 provinces, with access to over 19,000 hospitals and 20,000 pharmacies. Its collaborations with multinational pharmaceutical companies and leading research institutions have enriched its product portfolio, particularly in therapy areas such as oncology, cardiovascular, respiratory, and renal diseases. A notable product in its line is Vascepa®, a prescription medication that lowers triglyceride levels without raising LDL cholesterol. Eddingpharm has been granted development and commercialization rights for Vascepa® in mainland China, Hong Kong, Macau, and Taiwan, and is currently conducting clinical trials to support its regulatory registrations. The company's commitment to professionalism, excellence, responsibility, and persistence underpins its mission to enhance treatment options for patients in China.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Yulu Qianxing is an AI-powered platform that focuses on quantum mechanics, and molecular simulation algorithms to enable novel drug research and development by simulating processes.